Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | Comparison of the Simoa and MSD R-PLEX assays to assess serum NfL levels in ATTR amyloidosis

Milou Berends • 27 May 2024
ISA 2024
Amyloidosis Rare Diseases

In this video, Milou Berends, MD, PhD, University Medical Center Groningen, Groningen, The Netherlands, shares insights into a study in which two assays used to measure serum neurofilament light chain (NfL) levels in transthyretin (ATTR) amyloidosis were compared. This study demonstrated that the efficacy of both assays was similar. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Milou Berends

Diagnostic yield of a new multigene panel test in patients with suspected cardiac amyloidosis
1:44
Diagnostic yield of a new multigene panel test in patients with suspected cardiac amyloidosis
Milou Berends • 27 May 2024
Serum neurofilament light chain as an early disease biomarker in ATTR amyloidosis
1:44
Serum neurofilament light chain as an early disease biomarker in ATTR amyloidosis
Milou Berends • 27 May 2024

Related Videos

How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
1:40
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju • 30 May 2026
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
2:20
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
Naveen Pemmaraju • 29 May 2026
The importance of alloSCT in improving outcomes for patients with BPDCN
1:40
The importance of alloSCT in improving outcomes for patients with BPDCN
Naveen Pemmaraju • 29 May 2026
The content of VJHemOnc is intended for healthcare professionals